Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC), often diagnosed at advanced stages without curative therapies, is the fifth most common malignant cancer and the second leading cause of cancer-related mortality. Polo-like kinase 1 (PLK1) is activated in the late G2 phase of the cell cycle and is required...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Zhao, Zhen-Gang, Luo, Yin, Cui, Hao, Wang, Hao-Yu, Jia, Yan-Fang, Gao, Ying-Tang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459198/
https://www.ncbi.nlm.nih.gov/pubmed/32921957
http://dx.doi.org/10.3748/wjg.v26.i32.4786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459198/
https://www.ncbi.nlm.nih.gov/pubmed/32921957
http://dx.doi.org/10.3748/wjg.v26.i32.4786

Ejemplares similares